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Abstract
The COVID-19 pandemic is challenging modern radiation oncology. At University Hospitals, we have a mandate to
offer high-end treatments to all cancer patients. However, in times of crisis we must learn to prioritize resources,
especially personnel. Compromising oncological outcome will blur all statistics, therefore all measures must be
taken with great caution. Communication with our neighboring countries, within societies and between
departments can help meet the challenge. Here, we report on our learning system and preparation measures to
effectively tackle the COVID-19 challenge in University-Based Radiation Oncology Departments.
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Introduction
There is a nationwide concern about the coronavirus
disease 2019 (COVID-19) and immediate medical emer-
gency caused by the infection with severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2); currently,
this virus is the largest global public health threat lead-
ing to a major challenge of medical systems in all coun-
tries. The family of Coronaviridae consists of a group of
large, single, plus-stranded RNA-viruses which have
been isolated from several species; common symptoms
in humans include common cold and diarrheal illness
[1]. Almost 17 years ago, in China, a new coronavirus
termed Severe Acute Respiratory Syndrome Coronavirus
(SARS-CoV) caused the SARS outbreak and, within
weeks, spread to more than a dozen countries on several
continents including Asia, Europe, North and South
America. The crisis affected over 8000 humans and lead
to around 800 deaths [2].
As early as 2015, an international research group from
USA, Switzerland, and China reported on the pathogenic
potential of SARS-like Coronaviruses (CoVs) which were
at that time circulating in Chinese horseshoe bat popula-
tions [3]; the group extensively described that these vi-
ruses can replicate effectively in primary human airway
cells, and demonstrated the potential to affect the mouse
lung and lead to considerable pathogenesis. Alarmingly,
their experiments showed that available SARS-based
therapeutics, including immunotherapeutics, vaccines,
antibodies and other prophylactic modalities failed to
neutralize and protect from CoVs. While elucidating the
pathogenic potential, the authors warned of cross-
species transmission.
Only 5 years later, this virus has become a lethal treat
for humans; in December of 2019, Wuhan was the
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starting point of a worldwide pandemic, which sup-
posedly originated from Wuhan’s wild animal market
[4–6]. At the end of January 2020, the first case of a
positively tested patient was reported in Germany in
Munich, Bavaria, and according to the current status as
of March 22, 2020, 18,610 cases were reported in
Germany, including 55 deaths (https://www.rki.de/DE/
Content/InfAZ/N/Neuartiges_Coronavirus/Fallzahlen.
html).
Radiation Oncology (RO) is a key discipline in oncol-
ogy and currently more than 50–60% of all cancer pa-
tients are treated with radiotherapy at some point of
their disease [7]. Most curative treatment regimens in-
clude radiotherapy, many sequentially with surgery,
chemotherapy, or as concomitant treatments. Albeit the
fear of COVID-19 is currently crossfading all other ill-
nesses, it is the mission of radiation oncologists and
other cancer care physicians to courageously take sides
for our cancer patients.
We are now faced with increasing hygiene measures,
more complicated and difficult treatment procedures ag-
gravated by facial masks and personal protection equip-
ment [8]. The number of employee illnesses is
increasing and jeopardizing our efforts to secure con-
tinuous patient treatments. While most university-based
radiation oncology departments are equipped with high-
end radiotherapy devices which offer innovative radi-
ation treatments on a high and evidence-based level, hu-
man resources are the most precious asset in the
COVID-19 challenge.
Over the last years, independently of any pandemic
scenario, there has been a wave of arguments that
foster hypofractionated treatments in radiation oncol-
ogy. Most societies actively supporting those concepts
are clearly driven by a force of limited treatment cap-
acity paired with a constricted medical system; this
forefront is most actively driven by physicians in the
United Kingdom (UK). Others have followed, and in
indications such as breast cancer [9] and, now follow-
ing, prostate cancer, concepts of hypofractionation are
spreading [10]. While certain low-risk indications
might not be undertreated, there is a quiet word of
caution for high-risk, fast growing tumors and other
factors or tumor biology and normal tissue, that most
likely will lead to undertreatment with hypofractio-
nated regimens [11]. In metastatic disease, the argu-
ment for hypofractionation is clearly driven by the
reduced survival times of palliative patients; however,
lessons learned from the treatment of vertebral me-
tastases have nicely shown that short hypofractionated
treatments such as 5 × 4 Gy or 1 × 8 Gy for vertebral
metastases may help for short term pain reduction,
but longer-term local control is significantly lower
than with 10–13 × 3 Gy, and even higher with 40Gy
in 2 Gy fractions [12–18]. Estimating life expectancy
is always controversial, even among advanced health
care providers and with the help of high-end diagnos-
tic, molecular markers and prognostic scores, [19–25].
Now, in our world of high-end radiation oncology ser-
vice, we are facing a new challenge: keeping our radi-
ation oncology service up and running during the
COVID-19 challenge. In spite of specialized and
enforced hygiene measures, the crisis has triggered every
unit to activate and improve emergency scenarios. Con-
sidering potential limitations of personnel capacity, all
emergency measures will include, at a certain point,
hypofractionated and very pragmatic fractionation
schedules. These should ideally be evidence based. How-
ever, all measures must be associated with the appropri-
ate word of caution not to compromise oncological
outcome if not ultimately necessary due to collapsing
resources.
Preparing our radiation oncology departments should
therefore follow a series of regulations and measures, to
ensure high-end oncological treatment as long as
possible.
Overall, personell, patient and device hygiene are the
most important measure on wards, radiotherapy units,
chemotherapy treatment rooms, administration areas,
offices as well as all other public areas. Adequate disin-
fectants must be provided, at the entrance to the hos-
pital to the ward, to the radiotherapy unit etc., and
patients as well as staff must be educated on the effective
use of all disinfectants used. For superficial disinfectants,
it is important to use quickly active solutions so the
radiotherapy scheduling does not come to a standstill.
One critical issue in this special pandemic situation is
the availability of protective clothing. As long as suffi-
cient numbers of protective gear are available, surgical
masks should be worn according to the indications con-
tinuously updated by the World Health Organization
(WHO) [26], the Robert Koch Institute (RKI) [27], as
well as the respective hospital standard operating proce-
dures (SOP). Staff and patients must be advised that
masking protects both sides. The lesson of not protect-
ing the medical staff from the very beginning can be
drawn from the dramatic Italian experience. The medical
staff has become not only a casualty itself, but also a po-
tential source of infection that is transmitted to every
patient they meet and treat [28, 29]. In cases of SARS-
CoV-2 positivity, a more advanced personal protection
equipment is needed and includes: disposable overalls
(tunics and/or trousers), disposable gowns and eye pro-
tection should be used. FFP2 masks and overshoes are
not recommended in all institutions and countries. Visits
of relatives and accompanying people should be stopped
as early as possible to departments dealing with cancer
patients [30].
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 If the resources allow it, cancer patients, especially
those undergoing chemotherapy or those with
immunosuppression should wear adequate
protective masks. A recent analysis from Wuhan,
published in Lancet Oncology revealed that patients
with cancer might have a higher risk of COVID-19
than individuals without cancer. Additionally, the
study showed that patients with cancer had poorer
outcomes and more rapid deterioration from
COVID-19 [31, 32]. The authors even concluded,
that chemotherapy should be postponed if possible.
 In hospitals where there is no central triage unit, it
is recommended to carry out a triage at the
entrance of the radiotherapy facilities for the
verification of symptomatic patients or the
evaluation of contacts to SARS-CoV-2 positive pa-
tients in everyone accessing the radiotherapy areas.
Standardized questionnaires and measuring the body
temperature are advisable. Furthermore, outpatients
may be called by telephone 1 day in advance to their
appointments to screen for symptoms and ask for
contacts to SARS-CoV-2 positive patients/recent
stays in so called “risk areas”.
 Firstly, the management team of the Department
of Radiation Oncology must be clearly identified and
the executive power of each member of the
management team must be clarified and
communicated to the entire team in this special
situation. Secondly, the management team must be
divided into a tandem operation team (ideally
50% on site, 50% off site) to allow for backup
solutions. Through this measure it can be secured
that the executive force of the Department is not
compromised throughout the crisis. The
management team should communicate via
teleconferencing systems on a regular basis to
communicate all details and exchange any changes
of situation and not meet in person.
 The staff of the Department of Radiation Oncology
outside of areas ultimately relevant for the retention
of clinical department operations should be limited.
The offices, research areas, wards as well as other
clinical areas of the department should be restricted
to people working in system-critical areas. The
personnel may include staff for the basic operations
of the Department, including, in particular,
indispensable employees in administration and
patient care. For research areas, specific institutional
guidelines can be released. In some centers, critical
persons include personnel involved in animal
husbandry and animal research facilities, as well as
the supervisors of scientific long-term experiments
and technical infrastructure. In other scenarios, re-
search animal facilities are generally closed and all
staff is moved towards maintaining clinical infra-
structure and operations, as needed. The manage-
ment team should strictly supervise and coordinate
these measures and enable home-office possibilities.
 For all system-relevant areas, a tandem-staffing
must be planned at the earliest possible timepoint.
Tandems comprise two different persons who work
as back up for each other. They are not supposed to
be in physical contact, they are not allowed to enter
the same room at the same time. Importantly,
communication between tandems has to be ensured
at all time by digital means to maintain tandem
members at the same level of information. These
tandem teams should be built especially for doctors,
with special focus on the group of radiation
protection physicians to comply with regulatory
responsibilities at any timepoint of the crisis. Also,
technicians, medical physics experts (MPEs),
radiation safety officers as well as secretaries and
nurses should be places in tandem teams who stand
in continuous mutual consultation. These tandem
groups regularly switch on- and off-site assignments
every fortnight to overcome the 14-day half-life of
the SARS-CoV-2. Theses tandem groups depend on
the size and resources of the department, however,
even subgroup tandem-staffing could be a com-
promise solution.
 Some institutions recommend that all other staff
who is not working in system-critical areas
should work in home office, if possible. Special
assignments for the off-site work will be distributed
by the management team, the group leaders or other
supervisors. All off-site workers must be available to
supervisors as well as colleagues via landline, mobile
phone or e-mail. However, if this is not possible and
on-site working is performed, social distancing and
special hygiene requirements are essential. Digital
communication should be evaluated were possible.
 In order to meet the special challenges of these days,
management and the works council of some
institutions have reached an agreement on the
subject of “confidential working hours”, which
makes the current situation easier for both
employers and employees. This means, the employer
is not actively checking working hours, and at some
institutions electronic time recording is de-activated
since many individuals will be working off-site or in
home office situations.
 All planned leave days of personnel essential for
clinical operations should be cancelled during the
team of crisis. This ensures that essential workforce
is present and can be recruited to the department as
necessary. Another option is to remain on stand-by,
for immediate deployment when other personnel is
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absent. In all other groups of the workforce not es-
sential for clinical operations staff may be asked to
take all vacation days possible during this time.
 Conferences and interdisciplinary tumor boards
should be switched to digital solutions like email
and video conferences. If this is not possible, only
relevant staff with executive functions or experts
should participate to minimize group size and
exposure in order to prevent viral spread between
staff and different departments.
 Interdisciplinary case discussions (tumorboards) are
a standard in oncology. In these special times, these
discussions should not be compromised. Rather,
these conferences should be strengthened and
intensified to find the optimal solution for each
patient together with the neighboring disciplines,
such as hematology/oncology and surgery.
 All follow-ups should be critically evaluated and
postponed if not regarded essential. Outpatient
clinics are advised to use online, digital or medical
counselling by phone. However, it is important to
secure appropriate identification and treatment of
critical cases. For all outpatient clinics as well as
necessary follow-ups, entry point screening is neces-
sary; patients should fill out a hygiene risk question-
naire asking for possible symptoms and potential
residency or travel history to risk areas.
 In order to minimize the risk for both the patients
and health care staffing by the repetitive risk of
exposure, the indications for radiotherapy must be
strictly defined. Table 1 gives an evidence-based
overview of possible hypofractionated regimens or
observational strategies for a variety of entities
which can be considered during this crisis. The po-
tential benefits and risks of altered fractionations
should be carefully discussed with the patient. Pro-
crastinating certain pathologies by evaluating the
risk/benefit ratio in each individual case is advisable.
Moreover, benign diseases should not be treated at
all. Importantly, this table does not represent
standard-of-care regimens and the fractionations
should not be used routinely outside of special
crisis situations.
 In times were surgical and anesthesiological capacity
might become even more rare, the equieffectivity
of radiotherapy and radiochemotherapy
regimens as non-invasive treatments should be
discussed. For selected indications, literature is
summarized in Table 2, 3 and 4.
 Prepare staff and patients how to best mitigate the
impact of a 2- to 3-week interruption in treatment.
From the aftermaths from hurricane Maria in Puerto
Rico there are rough ASTRO guidelines based on
the limited evidence available [73–76].
 If possible members of the staff at high risk for
severe COVID-19 courses of disease should be iden-
tified and, if possible from an organizational point of
view, allotted to off-site assignments to allow for op-
timal social distancing and staff protection. This
may include older employees, those with comorbidi-
ties or other factors.
As long as possible, the provision of high-end onco-
logical care should be maintained. The despair of several
Italian and Spanish Radiation Oncology Departments in
the emerging COVID-19 crisis argued for triage and ex-
tensive application of hypofractionated and ultimately
ultra-hypofractionated radiation regimens [8, 77]. Al-
though the overall pandemic situation might force indi-
viduals for this strategy, it must be always kept in mind
that oncological care should not be compromised if not
ultimately needed, especially in the curative setting.
Additionally, all statistics of survival will be massively
blurred if broad radiation oncology service is restricted
and COVID-19 fear and pandemic crisis force us to use
minimalistic radiation efforts.
While most recommendations from other radiation
oncology societies are in line with the above-mentioned
measures during the COVID-19 outbreak, the treatment
of COVID-19 positive patients remains the greatest
challenge.
 A continuous triage evaluation is needed to detect
an early onset of typical symptoms of COVID-19
(fever, cough, sore throat, shortness of breath, fa-
tigue) in patients already receiving treatments at the
Radiation Oncology Department. This should imme-
diately be reported to the management team. Ad-
equate testing and reporting to authorities in
positive cases is mandatory. RKI criteria 3 and 4
should be applied to separate patients into those
with a less well-founded suspicion: acute respiratory
symptoms with/without fever and no stay in regions
with COVID-19 cases or clinical/radiological viral
pneumonia without alternative diagnosis without ex-
position risk.
 In patients who are already undergoing radiotherapy
and are suspected of having typical COVID-19
symptoms, the treatment should be immediately
interrupted, and testing results should be awaited.
 In COVID-19 positive patients, who have not started
treatment, it is recommended to postpone treatment
initiation whenever medically feasible and does not
compromise outcome, survival or quality of life
(QoL).
 In SARS-CoV-2 positive patients already undergoing
radiotherapy, the continuation of treatment can only
proceed when specific measures are taken. Each
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Table 1 Evidence-based recommendations for fractionated-adapted pandemic radiation oncology
Site Criteria Concept Evidence/ Guideline
Glioblastoma KPS 100–80; age > 65/60 years 2.67Gy/ 40.05 Gy + TMZ (MGMT methylated) Perry et al., 2017 [33]
KPS < 60 5.0 Gy / 25.0 Gy, no TMZ Roa et al. JCO 2005 [34]
KPS < 50; age > 70 years TMZ mono (MGMT methylated) or BSC Malmström et al. 2012 Lancet Oncology [35]
All age groups, good performance
status
Tumor treating field, especially if TMZ is postponed
due to pandemic risk for severe pneumonia
Stupp et al. JAMA 2015 [36]
Brain
metastases
1–10 BM; good performance
status
Stereotactic radiosurgery 1 × 18 Gy, or 1 × 20 Gy Kocher et al. JCO 2011 [37]
Yamamoto et al. Lancet Oncology 2017 [38]
Postoperative SRS of resection cavity e.g. 7 × 5 Gy or single fraction Brown et al. Lancet Oncology 2017 [39]
Mahajan et al. 2017 [40]
Sahgal et al., 2017 [41]
Driver mutations ALK: Targeted therapy first various
Life expectancy > 3 months 5 × 4 Gy Whole Brain Radiotherapy (WBRT) Borgelt et al. RED Journal 1981 [42]
Poor performance status Evaluate BSC with critical view of steroids Mulvenna et al. Lancet 2016 [43]
NCCN Guidelines
Meningeoma WHO°1 Watchful waiting or
5 × 5 Gy
NCCN Guidelines
Alfredo et al. 2019 [44]
WHO°2 Watchful waiting after complete resection NCCN Guidelines
EANO Goldbunner et al. Lancet Oncology 2016 [45]
RTOG 0539 Rogers et al.
J Neurosurg 2018 [46]
Breast DCIS Omission of RT in low risk DCIS or
Active surveillance + endocrine therapy or
15 × 2.67/ 40.05 Gy
Nilsson et al. Radiother Oncol 2015 [47]
Invasive Breast cancer Omission of RT in low risk carcinomas
or
15 × 2.67Gy/ 40.05Gy
or
5 × 5.2 /26Gy
Haviland et al. Lancet Onc. 2013 [48]
FAST Forward Trial [49, 50]
Including lymphatic drainage 15 × 2.67Gy/ 40.05Gy Haviland et al. Lancet Onc. 2013 [48]
Postmastectomy Hypofractionation if no implant,
15 × 2.67Gy/40.05Gy or 15 × 2.9/43.5 Gy
Wang et al. 2019 [51]
Partial breast ASTRO PBI criteria
38.5 Gy/ 10 fx BID
30 Gy/ 5 fx daily
28.5 Gy/ 5 fx once weekly
26Gy / 5 fx daily
20 Gy/ 1 fx IORT
Correa et al., 2017 [52]
Livi et al. Eur J of Cancer 2015 [53]
Brunt et al. FAST Forward Trial 2016 [49, 50]
Vaidya et al. Lancet 2014 [54]
Veronesi et al. Lancet Onc 2014 [55]
Lung NSCLC Stage I SBRT e.g. 3 × 15 Gy, 8 × 7.5 Gy, 1x34Gy [56] Guckenberger et al. J Thoracic Onc 2013 [57]
NSCLC stage III 24 × 2.75 Gy DOI: https://doi.org/10.1016/j.ejca.2006.09.005







































Table 1 Evidence-based recommendations for fractionated-adapted pandemic radiation oncology (Continued)
Site Criteria Concept Evidence/ Guideline
Prostate Low risk Postpone Therapy perhaps with ADT, active surveillance or
hormonotal deprivation
NCCN Guidelines
Active Surveillance Hamdy et al. & Donovan et al. NEJM 2016 ProtecT [60]
Watchful waiting Life expectancy < 10 years, T1–4, GS ≤7 NCCN Guidelines
Intermediate Risk or high Risk neoadjuvant ADT 2–3 months DART01/05
GICOR
Zapatero et al. Lancet Oncol 2015 [61]
EORTC 22991 Bolla et al. JCO 2016 [62]
20x 3Gy / 60Gy CHHIP Dearnaley et al.,2016 and 2017 [63, 64]
age < 75 years: 42.7 Gy/ 7 Fx every other day HYPO-RT-PC, Widmark et al., [65]
Adjuvant/ Salvage Situation Watchful waiting or ADT NCCN Guidelines
52.5 Gy / 20 fx Chin et al. RED Journal 2020
Lymphatic drainage RT Evaluate critically, only if visible nodal disease GETUG-01-Trial Pommier et al., J Clin Oncol 2007 and IJROBP 2016 Supiot
et al. 2013 [66–68]
Palliative
setting
Bone metastases 8 or 10 Gy/ 1 fx
20 Gy/ 5 fx
21 Gy/ 3 fx
Chow et al. JCO 2007 [69]
Head & neck QUADshot: 3.5 Gy BID × 2 days, repeated Q4 weeks interval × 2 times Spanos et al. Int J Radiat Oncol Biol Phys. 1989 [70]
Bleeding 8 Gy / 1 fx Sapienza et al. Clinical and Translational Radiation Oncology 2019 [71]
Oligometastatic SBRT, e.g. 1–5 fractions Otake et al. Cancers 2019 [72]







































Table 2 Esophageal Cancer. Neoadjuvant Therapy plus surgery vs. surgery versus definitivie Radiochemotherapy
Kranzfelder et al. Br J Surg 2011 Metaanlysis
Nine RCTs involving neoadjuvant CRT versus surgery, eight involving
neoadjuvant chemotherapy versus surgery, and three involving
neoadjuvant treatment followed by surgery or surgery alone versus dCRT
Neoad. RChT:
Sign. OS-Benefit (HR 0,81)
Neoadj. ChT:
No OS-Benefit (HR 0,93, p = 0,36)
No OS difference after dCRT demonstrated a significant survival benefit, but
treatment-related mortality rates were lower (HR 7·60, P = 0·007) than with
neoadjuvant treatment followed by surgery or surgery alone.
Stahl et al. JCO 2005 Phase III-Study (1994–2002, 189 Pat.)
CRT: 40 Gy + Cisplatin/Etoposid vs. def. RCHT
adding surgery to chemoradiotherapy improves local tumor control but
does not increase survival of patients with locally advanced esophageal
SCC. Tumor response to induction chemotherapy identifies a favorable
prognostic group within these high-risk patients, regardless of the
treatment group.
FFCD 9102
Bedenne et al. JCO 2007
Phase III-Study (1993–2000, 259 Pat.)
T3 N0–1, 89% SCC
Neoadj. CRT: Split course 30 Gy in 3 Gy or 45 Gy in 1,8 Gy + 2x Cisplatin/5-FU
Random.: OP vs. def. CRT
two-year survival rate was 34% in arm A versus 40% in arm B (hazard ratio
for arm B v arm A = 0.90; adjusted P = .44). Median survival time was
17.7 months in arm A compared with 19.3 months in arm B
Author conclusion: there is no benefit for the addition of surgery after







































Table 3 Radiotherapy/Radiochemotherapy for Rectal Cancer
Maas, JCO, 2011 Patients with a cCR after CRT were prospectively selected for the wait-and-see policy
with magnetic resonance imaging (MRI) and endoscopy plus biopsies
prospective cohort study
21 patients
control group: FU 35 Mo, 2-J-DFS 93%, 2-J-OS 91%
control group consisted of 20 patients with a pCR after surgery who had a
mean follow-up of 35 ± 23months. For these patients with a pCR,
cumulative probabilities of 2-year disease-free survival and overall
survival were 93 and 91%, respectively.
Habr-Gama, IJROBP 2014 183 Pat., cT2–4 or N+, CRT (50–54 Gy + 5-FU), Response after 8 weeks, patients with
cCR were enrolled in a strict follow-up program with no immediate surgery (Watch
and Wait).
Local recurrence may develop in 31% of patients with initial cCR when
early regrowths (≤ 12months) and late recurrences are grouped together.
More than half of these recurrences develop within 12months of follow-up.
Salvage therapy is possible in ≥90% of recurrences, leading to 94% local





RChT, if cCR no surgery
38% 3 J LR, 88% Salvage-OP, better colostomy-free survival (74% vs 47%)
in R T group
A substantial proportion of patients with rectal cancer managed by watch
and wait avoided major surgery and averted permanent colostomy
without loss of oncological safety at 3 years.
Appelt et al. Lancet Oncol
2015
prospective cohort study (2009–2013, 51 Pat.), Follow up 29 months
CRT with 50 Gy incl. SIB 60 Gy + HDR-Brachy 1 × 5 Gy + Tegafur-Uracil 300 mg/m2
40 Pat. With cCR (78%)
Local recurrence in the observation group at 1 year was 15·5% (95% CI 3·3–26·3).
The most common acute grade 3 adverse event during treatment was diarrhoea,
which affected four (8%) of 51 patients. Sphincter function in the observation
group was excellent, with 18 (72%) of 25 patients at 1 year High-dose
chemoradiotherapy and watchful waiting might be a safe alternative to
abdominoperineal resection for patients with distal rectal cancer.
Garcia-Aguilar et al. Lancet
Oncol 2015 ACOSOG Z6041
29
Phase II-study (77 Pat.), FU 52 Mo.
cT2 N0 < 4 cm (EUS oder MRT) neoadj. CRT 50–54 Gy + Oxaliplatin/Capecitabine
after 4–8 weeks local excision for patients with stage T2N0 rectal cancer.
3-year DFS 88%







































Table 4 Stereotactic Body Radiotherapy (SBRT) vs. Surgery for lung cancer
ROSEL/ STARS
Chang (Lancet Oncol 2015)
58 Pat. 2 rand., prosp. Studies
T1–2 N0, < 4 cm
54 Gy in 3 Fx (peripher) o. 50 Gy in 4 Fx (zentral) vs. surgery
SBRT vs. surgery
3y-OS: 95 vs. 79% (s)
LC: 94% vs. 100% (n.s.)
>°III Tox: 10 vs 44%
Zheng et al. IJROBP 2014 Metanalyse, 40 studies of SBRT and 23 Studies with surgery St. I NSCLC
Median Age 74 J. vs. 66 J.
5-year OS 40% vs. 66% (lobectomie) vs. 71%
(sublobectomie)
Stokes et al. JCO 01/2018
30 & 90 day mortality
National Database, 76,623 patients OP (78% lobectomy, 20% sublobar resection,
2% pneumonectomy) vs. 8216 patients SBRT
Propensity score matching
surgical mortality rates were significantly
higher with increased extent of resection and age at








































department should individually weigh their re-
sources and evaluated on a case by cases basis (indi-
cation for treatment, performance status of the
patient, etc.). If these prerequisites cannot be met, a
discontinuation of treatment is mandatory. Espe-
cially, as the case load of SARS-CoV-2-positive pa-
tients is increasing significantly, a strict no-RT-
policy can be decided.
 If treatment continues, these measures must be
taken:
○The treatment has to be carried out under
maximal safety conditions to guarantee the
protection of health professionals.
○The patients should be treated at a special linear
accelerator, with a specific access route to
prevent contact to other patients. This can for
example be performed at the end of the regular
treatment schedules.
○The staff needs appropriate personal protection
equipment according to institutional guidelines
and availability.
○The equipment and linac must be adequately
sanitized at the end of treatment.
 Alternatively, all treatments in SARS-CoV-2 positive
patients could be interrupted to avoid infections of
the staff and other patients
 In SARS-CoV-2 positive patients declared cured
from the disease, a careful evaluation has to be per-
formed prior to proceed radiotherapy with less ad-
vanced measures.
Taken together, the way we treat cancer in the coming
months will change dramatically during this pandemic.
While we are used to counselling patients on their best
treatment option, we will be confronted with a whole
new dimension – where we will have to balance the ben-
efits of oncological therapies against the increased risk
of cancer patients for SARS-CoV-2 infections. The indi-
cations and timelines of our radiotherapy treatments
may shift, and we might accept higher risks of cancer re-
currences over a short-term increase in risk of death
from COVID-19. Despite the increased anxiety and un-
certainty that all cancer patients face while awaiting
time-dependent treatments, this could even be worse
during these days of social distancing and unavailable
treatment options. Please consider this aspect during
your clinical routine. The selected and presented scien-
tific evidence, it’s interpretation and translation into ra-
diation oncology specific recommendations by this
multi-institutional and international collaboration need
to be put into the very special context of the COVID-19
pandemic. Firstly, there is still very little knowledge or
even evidence available, yet. Available data is sometimes
conflicting and incomplete. This knowledge is luckily
expanding at enormous speed, which makes however the
generation of a founded synthesis difficult. In such a dy-
namic situation, this manuscript therefore reflects a
snapshot, which may become outdated rapidly. Recom-
mendations aim to maximize cancer care of all patients,
best-as possible protection of our health care workers
and simultaneously rigid suppression of the pandemic
spread. It is obvious that not all three goals can be
followed and can be achieved to 100%, compromises in
one or the other way will have to be made. Such multi-
factorial problems will require difficult decisions: deci-
sions will be influenced by various stakeholder (govern-
ment, health authorities, hospital and university
administration), will be restricted by logistical and finan-
cial aspects, will need to follow the respective legal
frameworks, will need to be put into the political and
cultural context, and will at the same time need to con-
sider the individual patient and their families. Conse-
quently, there will be differences between countries,
states, institutions and even between individual clini-
cians, all trying their best in such situations of crisis. Fi-
nally, we do not know, yet, whether the structured
planning described in this manuscript will stand or sur-
vive the potentially dramatic developments in the future,
where irrational or hard actions might become reality.
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